REPRESENT-PF Registry
Recruiting now
Conditions studied: Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation
In brief
This pragmatic, prospective, single-arm, multi-center, observational registry will evaluate the safety and effectiveness of PFA for the treatment of atrial fibrillation in underrepresented minority patients using FDA approved Boston Scientific PFA catheters; all data collected will be standard of care.
Key facts
- Study ID
- NCT07535268
- Run by
- Vivek Reddy
- People needed
- 275
- Starts
- 2026-03-30
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2026-04-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- All consecutive patients classified as racial or ethnic minorities undergoing ablation using Boston Scientific FDA approved PFA catheters for AF will be included.
- De novo ablation for symptomatic paroxysmal and persistent AF (Age ≥ 18) (unless it is a repeat for a patient whose index procedure is also in the registry) who are deemed to be candidates for AF ablation by the investigator.
- Able and willing to participate in baseline and follow up evaluation over the study period
- Willing and able to provide informed consent, if applicable.
You may not qualify if…
- Enrolled in an investigational drug or device clinical trial or any other trial with outlined treatment plan
- Long standing persistent AF (AF > 1 year duration)
- Repeat ablation, unless index ablation procedure was in the REPRESENT-PF registry
- Any known contra-indication to ablation procedure at the discretion of the investigator
Where it is running
- The Mount Sinai Hospital — New York, New York, United States (enrolling)
- Valley Health System — Winchester, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.